瑞典南部活检确诊巨细胞动脉炎的流行病学:发病率更新与首次患病率估计
结果显示年均发病率为13.3/10万(≥50岁),且呈逐年下降趋势,同时首次报告了该地区GCA的时点患病率。
要点
- 活检阳性GCA年均发病率13.3/10万(≥50岁),女性高于男性。
- 年龄和性别标化发病率从1997年17.3降至2019年8.7,年发病比0.98。
- 总体时点患病率127.1/10万,仅接受免疫抑制治疗者75.5/10万。
核心结论
- 过去二十年间活检确诊GCA发病率每年下降约2%,但当前治疗中的GCA患病率仍较高。
- 春季和夏季诊断病例多于冬季。
研究设计与样本
- 回顾性分析1997–2019年瑞典斯科讷地区所有颞动脉活检病理报告,识别活检阳性GCA患者。
- 基于23年期间计算发病率,并确定2014年12月31日的时点患病率。
主要发现
- 1997–2019年平均年发病率为13.3/10万(95%CI:12.6,14.0),女性17.8(95%CI:16.7,18.9),男性8.2(95%CI:7.4,9.0)。
- 年龄和性别标化发病率从1997年17.3降至2019年8.7,年发病比0.98(95%CI:0.98,0.99)。
- 春季发病率高于冬季,发病比1.19(95%CI:1.03,1.39)。
- 总体时点患病率127.1/10万(95%CI:117,137.3),仅接受免疫抑制治疗者75.5/10万(95%CI:67.7,83.3)。
关键数值与推荐
- 活检阳性GCA年均发病率13.3/10万(95%CI:12.6,14.0),适用于≥50岁人群。
- 时点患病率127.1/10万(95%CI:117,137.3),仅接受免疫抑制治疗者75.5/10万(95%CI:67.7,83.3)。
临床怎么用
- 流行病学数据提示GCA发病率呈下降趋势,但患病率仍较高,临床需关注当前治疗中的患者管理。
- 季节 variation 提示春夏季诊断病例较多,可结合临床警惕。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the epidemiology of temporal artery biopsy-positive (TAB+) GCA, including trends in incidence, seasonal variation and prevalence in Skåne, the southernmost region of Sweden. METHODS: All histopathology reports of TABs from 1997 through 2019 were reviewed to identify patients diagnosed with TAB+ GCA. Incidence rates based on the 23-year period and the point-prevalence at 31 December 2014 were determined. An alternative prevalence calculation included only TAB+ GCA patients living in the study area and receiving immunosuppressant therapy on the point-prevalence date. RESULTS: One thousand three hundred and sixty patients were diagnosed with TAB+ GCA (71% female). The average annual incidence 1997-2019 was 13.3 (95% CI: 12.6, 14.0) per 100 000 inhabitants aged ≥50 years and was higher in females (17.8; 95% CI: 16.7, 18.9) than in males (8.2; 95% CI: 7.4, 9.0). The age- and sex-standardized incidence declined from 17.3 in 1997 to 8.7 in 2019, with incidence ratio (IR) of 0.98 per year (95% CI: 0.98, 0.99). A seasonal variation was observed with higher incidence during spring than winter [IR = 1.19 (95% CI: 1.03, 1.39)]. The overall point-prevalence of TAB+ GCA was 127.1/100 000 (95% CI: 117, 137.3) and was 75.5 (95% CI: 67.7, 83.3) when including only patients receiving immunosuppressants. CONCLUSION: Over the past 2 decades, the incidence of biopsy-confirmed GCA has decreased by ∼2% per year. Still, a high prevalence of GCA on current treatment was observed. More cases are diagnosed during spring and summer than in the winter.
引用
- Stamatis P, Turkiewicz A, Englund M, et al. Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden-an update on incidence and first prevalence estimate. Rheumatology (Oxford). 2021. PMID: 33742665. doi:10.1093/rheumatology/keab269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。